Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
Atea Pharmaceuticals presented Phase 1 data at EASL Congress 2026 showing its lead HCV regimen, BEM/RZR, has a low risk of drug-drug interactions with common medications like omeprazole and rosuvastatin. The results support co-administration without dose adjustments, reinforcing the regimen's potential best-in-class profile as the company approaches topline Phase 3 results from the C-BEYOND and C-FORWARD trials.
Key figures
- Drug Name
- BEM/RZR (bemnifosbuvir and ruzasvir)
- Phase Of Trial
- Phase 1
- Hev asset
- AT-587
- Ruzasvir subjects
- over 2,800
- Hcv phase 3 trials
- C-BEYOND, C-FORWARD
- Hev potency vs sof
- 30 to 150-fold more potent
- Bemnifosbuvir subjects
- over 3,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.